1-[4-Hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-(hydroxymethyl)pyrimidine-2,4-dione | 5116-24-5

• 物质功能分类: 生物化工 - 核苷类药物 - 脱氧核苷酸及其类似物
• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘧啶核苷
• 英文名称: 1-[4-Hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-(hydroxymethyl)pyrimidine-2,4-dione
• CAS: 5116-24-5
• 化学式: C₁₀H₁₄N₂O₆
• 分子量: 258.23
• InChiKey: IPAVKOYJGUMINP-UHFFFAOYSA-N

物化性质

• 熔点：
  176-179 °C
• 沸点：
  401.48°C (rough estimate)
• 密度：
  1.3598 (rough estimate)
• 溶解度：
  DMSO（轻微、超声处理）、甲醇（轻微、加热）、水（轻微）

计算性质

• 辛醇/水分配系数(LogP)：
  -1.9
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  119
• 氢给体数：
  4
• 氢受体数：
  6

安全信息

• 安全说明：
  S24/25
• WGK Germany：
  3
• 海关编码：
  2934999090
• 危险性防范说明：
  P501,P270,P264,P280,P302+P352,P337+P313,P305+P351+P338,P362+P364,P332+P313,P301+P312+P330
• 危险性描述：
  H302,H315,H319

文献信息

• Treatment of EBV and KHSV Infection and Associated Abnormal Cellular Proliferation
  申请人：Schinazi Raymond F.

  公开号：US20100168052A1

  公开（公告）日：2010-07-01

  A method and composition for the treatment, prevention and/or prophylaxis of a host, and in particular, a human, infected with Epstein-Barr virus (EBV), is provided that includes administering an effective amount of a 5-substituted uracil nucleoside or its pharmaceutically acceptable salt or prodrug, optionally in a pharmaceutically acceptable diluent or excipient.

  本发明提供了一种用于治疗、预防和/或预防宿主，特别是人类，感染EB病毒（EBV）的方法和组合物，其中包括在药物接受者中给予有效量的5-取代尿嘧啶核苷或其药学上可接受的盐或前药，可选地在药学上可接受的稀释剂或赋形剂中。
• TREATMENT OF EBV AND KHSV INFECTION AND ASSOCIATED ABNORMAL CELLULAR PROLIFERATION
  申请人：GILEAD PHARMASSET LLC

  公开号：US20140336143A1

  公开（公告）日：2014-11-13

  A method and composition for the treatment, prevention and/or prophylaxis of a host, and in particular, a human, infected with Epstein-Barr virus (EBV), is provided that includes administering an effective amount of a 5-substituted uracil nucleoside or its pharmaceutically acceptable salt or prodrug, optionally in a pharmaceutically acceptable diluent or excipient.

  提供一种用于治疗、预防和/或预防寄主，特别是人类，感染EB病毒（EBV）的方法和组合物，其中包括在药学上可接受的稀释剂或赋形剂中投与有效量的5-取代尿嘧啶核苷或其药学上可接受的盐或前药。
• SYNERGISTIC ENHANCEMENT OF 5-FLUOROURACIL CYTOTOXICITY BY DEOXYURIDINE ANALOGS IN CANCER CELLS
  申请人：Ide Hiroshi

  公开号：US20180125875A1

  公开（公告）日：2018-05-10

  In one embodiment, the invention provides a method of treating a subject who suffers from a neoplasm (including a cancer such as a radiotherapeutic-resistant cancer) by administering to the subject a therapeutically effective amount of (a) 5-formyl-2′-deoxyuridine (fdU or foUdR) or a 5-formyl-2′-deoxyuridine derivative, optionally in combination with 5-hydroxy-2′-deoxyuridine (hUdR); and (b) at least one composition selected from the group consisting of either 5-fluorouracil (5-FU), a 5-FU prodrug (e.g. 5-fluoro-2′-deoxyuridine (FdU)) or 5-FU metabolite. In a preferred embodiment, a subject who suffers from colorectal cancer (CRC) or metastatic colorectal cancer (mCRC) is treated with a therapeutically-effective amount of fdU and either 5-FU or the 5-FU prodrug 5-fluoro-2′-deoxyuridine (FdU). Related pharmaceutical compositions are also provided.
• US9382286B2
  申请人：——

  公开号：US9382286B2

  公开（公告）日：2016-07-05